GlassScriptPhysician profile
Lisa B Morgan
NPI 1437152485
$5,184.30
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $182 · 2021: $741 · 2022: $672 · 2023: $499 · 2024: $2,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,400 · Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,400.00 |
| Food and Beverage | $807.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,400.00 | 2024 | |
| Abbvie INC. | $613.32 | 2019-2023 | |
| Coopersurgical, INC. | $432.81 | 2019-2024 | Endosee, Paragard T 380a |
| Aspira Women'S Health INC | $289.39 | 2021-2024 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $271.26 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $190.34 | 2021-2023 | |
| Exeltis, USA INC. | $126.81 | 2020-2024 | Slynd |
| Daiichi Sankyo INC. | $90.36 | 2019-2022 | |
| Organon LLC | $83.80 | 2021-2024 | Nexplanon |
| Agile Therapeutics, INC. | $81.62 | 2021-2022 | |
| Millicent US INC | $63.30 | 2023-2024 | Intrarosa, Femring |
| Therapeuticsmd, INC. | $43.70 | 2021-2022 | |
| Channel Medsystems, INC. | $42.46 | 2024 | |
| Avion Pharmaceuticals | $41.12 | 2019-2021 | |
| Amgen INC. | $40.63 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.24 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $39.24 | 2019 | |
| Duchesnay USA Incorporated | $39.19 | 2019 | |
| Allergan, INC. | $35.57 | 2019 | |
| Pfizer INC. | $25.89 | 2020-2021 | |
| Octapharma USA, INC. | $25.08 | 2024 | Balfaxar |
| Mylan Pharmaceuticals INC. | $23.99 | 2019 | |
| Hologic Sales and Service, LLC | $17.95 | 2023 | Aptima |
| Shield Therapeutics INC | $16.86 | 2023 | Accrufer |
| Roche Diagnostics Corporation | $16.11 | 2020 | |
| Minerva Surgical, INC | $14.73 | 2019 | |
| Medtronic, INC. | $14.23 | 2023 | Truclear |
| Vertical Pharmaceuticals, LLC | $13.59 | 2019 | |
| Olympus America INC. | $13.53 | 2023 | Olympus |
| Boston Scientific Corporation | $13.20 | 2020 | |
| Scynexis, INC. | $12.76 | 2022 | |
| Evofem Biosciences, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.